Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
He is the only one that should have stayed with Varney.
The tools to sell the technology have always been there!
*
o Development/Plasticity/Repair
AMPA Receptor-Induced Local Brain-Derived Neurotrophic Factor Signaling Mediates Motor Recovery after Stroke
1. Andrew N. Clarkson1,
2. Justine J. Overman1,
3. Sheng Zhong2,
4. Rudolf Mueller2,
5. Gary Lynch3,4, and
6. S. Thomas Carmichael1
+ Author Affiliations
1.
1Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California 90095,
2.
2Cortex Pharmaceuticals, Inc., Irvine, California 92618, and
3.
3Departments of Psychiatry and Human Behavior and
4.
4Anatomy and Neurobiology, University of California, Irvine, Irvine, California 92697
+ Author Notes
*
A. N. Clarkson's present address: Departments of Psychology and Anatomy and Structural Biology, University of Otago, P.O. Box 913, Dunedin 9013, New Zealand.
Abstract
Stroke is the leading cause of adult disability. Recovery after stroke shares similar molecular and cellular properties with learning and memory. A main component of learning-induced plasticity involves signaling through AMPA receptors (AMPARs). We systematically tested the role of AMPAR function in motor recovery in a mouse model of focal stroke. AMPAR function controls functional recovery beginning 5 d after the stroke. Positive allosteric modulators of AMPARs enhance recovery of limb control when administered after a delay from the stroke. Conversely, AMPAR antagonists impair motor recovery. The contributions of AMPARs to recovery are mediated by release of brain-derived neurotrophic factor (BDNF) in periinfarct cortex, as blocking local BDNF function in periinfarct cortex blocks AMPAR-mediated recovery and prevents the normal pattern of motor recovery. In contrast to a delayed AMPAR role in motor recovery, early administration of AMPAR agonists after stroke increases stroke damage. These findings indicate that the role of glutamate signaling through the AMPAR changes over time in stroke: early potentiation of AMPAR signaling worsens stroke damage, whereas later potentiation of the same signaling system improves functional recovery.
I hope they read these posts. The best case scenario would be they get so pissed and defensive that they turn off the video poker machines and go to work.
This is true, but don't forget, all was done at the expense of others. Wrong, immoral, and unforgivable!
Clinical Trial of Ampakine CX516 in Adults with Fragile X
by Elizabeth Berry-Kravis, 6/1/2006
The Ampakine trial with AMPA receptor activator CX516 has now been completed. This trial was initiated because of findings of reduced AMPA receptors and AMPA-mediated LTP (long term potentiation; a form of memory) in cerebral cortex of the fragile knockout mouse. The trial consisted of a Phase II 4-week randomized double-blind placebo-controlled clinical trial which was conducted to evaluate the safety and efficacy of the Ampakine CX516 as a potential treatment to correct the deficient AMPA activity as a means of treating the underlying brain disorder in fragile X syndrome (FXS). After baseline screening, 49 subjects with FXS underwent a one-week placebo lead-in, then were treated with study drug or placebo for 4 weeks. There were minimal side effects in the subjects with FXS who were treated with CX516, no significant changes in safety parameters, and no serious adverse events. There was a 12.5% frequency of allergic rash in the CX516 group and one subject developed a substantial rash. There was also no significant improvement in memory, the primary outcome measure, or in secondary measures of language, attention/executive function, behavior, and overall functioning in CX516-treated subjects compared to placebo. This study did demonstrate that many outcome measures were reproducible in this test-retest setting for the FXS population, yet some were too difficult or variable. Outcome measures (tests that measure improvement due to medication effect) that were shown to be reproducible will now be able to be used for future clinical trials of new medications in FXS. The study also showed that adult subjects with FXS were able to complete an intensive clinical trial with an excellent completion rate for all the tests required by the trial. Problems with potency of CX516 in other studies have suggested dosing may have been inadequate for therapeutic effect. In fact, when only subjects treated with an antipsychotic upon entering the CX516 study were analyzed, there appeared to be improvement in global cognitive and behavioral functioning in the CX516-treated group relative to the placebo group. Given the known ability of antipsychotics to potentiate the effect of CX516 in animal models, this would suggest that the CX516 was likely insufficiently potent. Thus it remains unclear whether modulation of AMPA-mediated neurotransmission is a viable therapeutic strategy for the treatment of FXS, but given the lack of major safety problems with CX516, and suggestion of effectiveness when combined with antipsychotics, it would be reasonable to propose further trials with more potent Ampakine molecules in the future. New, more potent ampakines which last longer in the body are being tested in the mouse model of fragile X (see FRAXA research projects of Dr. Julie Lauterborn). The outcome of this and other studies will help determine whether stronger ampakines may be effective in treating fragile X; new trials will be planned if stonger ampakines seem likely to help. We are grateful to the wonderful families and adult Fragile X subjects who have made the considerable effort required to participate in this study. They are helping lay the groundwork for future treatment of cognition in Fragile X syndrome.
© 2011 FRAXA Research Foundation, 45 Pleasant St., Newburyport, MA 01950. Tax ID: 04-3222167.
Editor/writers: Katie Clapp, MS, and Michael Tranfaglia, MD. Updated 8/2/2011. All rights reserved. Site designed and maintained by:
Lilac Design Studio, LLC
The point is their leadership, and focus will prevail.
Cortex had a fragile X study. Goggle Dr. Elisabeth Berry Kravis.
My son who suffers from Autism has seen her.
trials in process
We need to be a little more focused in our efforts too!
I mean, come on! ADHD, AD, SA,ETC. why not PMS!
fragile X study leaders
They have been focusing on this for years. Good management pays off.
They are getting closer.
Yes indeed! I think it's time for some quality reserves to come off of the bench and make some things happen....if it's not too late. Is it too late? Imagine what the right people could have done with the same compounds. Haysaw is right, we need Les, not more.
list of companies for Colmann to contact
Get off of your ass and do some work! Dig,dig,dig!
Find a partner, buyer, more important a good replacement!
I can't believe you would doubt the wisdom in Irvine.
More (Stoll) or Les (Street), tough choice. They are such a joke.
The big question is....
Is there anyone within Cortex capable of selling to them?
In-licensing requirements
About Shire
Shire Pharmaceuticals is a rapidly growing, international specialty biopharmaceutical company
Shire’s development focus is in central nervous system disorders, gastro-intestinal, regenerative medicine, human genetic therapies and orphan diseases
Shire has completed nine mergers and acquisitions in eleven years
In-licensing and product acquisitions are a priority at Shire
Why partner with Shire?
Shire has an impressive and balanced portfolio of products, many of which derive from successful external collaborations
Shire has a sales and marketing capability in major markets throughout the world
Partners benefit from Shire’s excellent track record of product development and commercialisation
Shire retains a flexible and creative approach to collaborations
Shire manages its collaborations in a rapid and responsible manner through a dedicated Alliance Management group
What are Shire’s in-licensing interests?
Depending upon the indication, collaborations may be formed at various stages of the development process
Shire welcomes approaches from potential collaborators with products that match Shire’s strategic focus areas
Is someone trying to accumulate at a very low price, or is someone trying to dump a large amount with very low interest? Thoughts anyone.
Glutenous pigs feeding off of anything and anyone.
I feel violated, oh the shame!
On a serious note, is there anyone at corporate who has considered looking for a buyer like Kevin Tang, or the Baker group?
What about it? Sell the dam thing before it melts away.
Think about it, other then RD, what is worth partnering.
Sleep Apnea is a stretch!
I really hate monkey brains!
Did he get to keep his poker winnings?
Unfortunately, even those who used too sing the praises of Cor have lost touch with management. Where are you all now? When was the last time we heard, I emailed MV. or, I spoke to Rodger. Why can't they send us an update. Are they too busy?
They are still there, and yes getting paid for their poor performance. The only movements we'll see on this stock now is from the penny stock Market makers.
No, the poor management has more to do with it.
[url][/url][tag]insert-thttp://theautismnews.com/2012/04/10/autism-research-may-be-about-to-bear-fruit/ext-here[/tag]
Cortex should have been the ones getting close to helping individuals with Autism.
Which stock quote is correct, corx.ob or corx.pk?
Sorry bunch, aren't they!
Take a close look at Bellus. New company forming from a $17 million dollar merger. Cheap right now
http://finance.yahoo.com/news/bellus-health-announces-17-million-120000965.html
It's good to see some companies know how to make things happen!
200 times .06 = $12.00
Wow! So sad....
Massive volume today. 200 shares @.06
It's true. The success of any company depends upon the leaders.
Vision is a prerequisite! They need some! A top notch sales/CFO.
No one on this board believes that the compounds are worthless.
Including you and I. We just agree the management is worthless.
I am on Varney's side, he was handed a bee's nest by Stoll, but he has more to work with now. Money is gone, but the basket of compounds is full.He will make this work, but he needs a new support team. Throw out the video poker machines, take away the credit cards, throw out the dead weight, and find a visionary team.
The industry is full of success stories. Yet all we hear from Neuro is you'll lucky if a big Pharma guy will buy you a cheese burger. I don't believe it! Call Kevin Tang. He loves to make winners out of losers.
http://www.smallcapnetwork.com/The-Best-Biotech-Stocks-for-2012/s/via/9846/blog/view/p/mid/1/id/2/[/url][tag]the best biotech stocks for 2012[/tag]
Where is Cortex? Why can't Coleman find his way out of the basement?
Fortunately for these biotech companies Colman doesn't work for them!insert-http://seekingalpha.com/article/467081-small-cap-biotech-stocks-being-accumulated-by-the-world-s-largest-money-managers?source=yahootext-here
Here is the CRO in action!
Some things never change in Irvine.
GFP, check out AP pharma. Alot going on there.
I am not wondering about it. Our day will come soon.
As the great PT Barnum said, "there is a sucker born everyday"
Babies are still being born aren't they? The cor savior may be delivered next week, all we'll have to do is wait for him or her to get through college, get about ten years of experience, and get sucked in.LOL
And the way it looks today we'll be able to get 391 shares for the price of a bottle of ripple soon!
Sad! They have to screw with pennies. But on the bright side, we can all own 391 shares for the price of a good bottle of bourbon.